Article - 12/12/2011 Comprehensive Biomarker Center GmbH – next-generation biomarkers Biomarker research has moved on from proteins to nucleic acids where one of the main priorities is the use of microRNA expression profiles. The Heidelberg-based biotech company Comprehensive Biomarker Center GmbH (CBC, formerly febit) has state-of-the-art technologies and the skills and knowledge to advance the development of new nucleic acid biomarkers for complex diseases in cooperation with partners from research and industry. https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-biomarker-center-gmbh-next-generation-biomarkers
Article - 19/12/2011 Lenhard Rudolph prepares four biomarkers for clinical application Lenhard Rudolph’s biomarker quartet is extremely promising in terms of progressing medical and clinical treatment in ageing societies. The quartet - EF-1 alpha, Chi3L3, CRAMP and OP 18 – is made up of four proteins that can potentially be used as biomarkers. Specific concentrations of these molecules in human blood provide information on the biological age and renewal capacity of the tissue and organs of patients. The biomarker quartet also…https://www.gesundheitsindustrie-bw.de/en/article/news/lenhard-rudolph-prepares-four-biomarkers-for-clinical-application
Dossier - 12/12/2011 Development of new molecular biomarkers Biomarkers are playing an increasing role in drug discovery and development. They can be used as molecular indicators for diseases and disease risks as well as for monitoring the effectiveness of therapy. Highly specific molecular biomarkers are being identified using state-of-the-art technologies from the fields of genomics, proteomics and metabolomics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/development-of-new-molecular-biomarkers
Article - 28/04/2014 Sciomics: antibody microarrays and their broad range of applications Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of…https://www.gesundheitsindustrie-bw.de/en/article/news/sciomics-antibody-microarrays-and-their-broad-range-of-applications
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Article - 12/12/2011 Rheumatoid arthritis biomarkers A plethora of biomarkers is available for the early diagnosis of rheumatoid arthritis and associated tissue damage and disorders. In addition, new biomarkers that improve the diagnosis and treatment of patients suffering from this common destructive autoimmune disease are constantly being discovered.https://www.gesundheitsindustrie-bw.de/en/article/news/rheumatoid-arthritis-biomarkers
Press release - 24/05/2017 High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures
Article - 10/02/2008 4th Biomarker Workshop at the NMI in Reutlingen: another success The Biomarker Workshop held at the NMI in late January has become a fixed date for a growing number of proteomics researchers. With an attendance of 130 this years workshop exceeded all previous ones. Those who were keen to find out more about the latest trends and findings were presented with a successful mix of basic and applied research information.https://www.gesundheitsindustrie-bw.de/en/article/news/4th-biomarker-workshop-at-the-nmi-in-reutlingen-another-success
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Article - 16/02/2008 New test for the early diagnosis of cervical cancer mtm laboratories has launched the Cervatec assay for the early diagnosis of cervical cancer. The Cervatec assay will initially be commercialized as an adjunct to the Pap test for the screening of women aged 35 and younger.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-test-for-the-early-diagnosis-of-cervical-cancer
Article - 28/11/2010 Genedata facilitates search for biomarkers Biomarkers play a key role in testing the efficacy of a new drug or finding out adverse reactions to it. For reliable and quick results, modern laboratory methods are used to generate huge amounts of highly complex molecular data. The data then need to be efficiently analysed. The company Genedata, with headquarters in Basel (Switzerland) and offices throughout Europe, including a base in Konstanz (Germany), has developed the software system…https://www.gesundheitsindustrie-bw.de/en/article/news/genedata-facilitates-search-for-biomarkers
Article - 17/03/2021 Epigenetic switches in bacteria as biosensors The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetic-switches-bacteria-biosensors
Article - 09/01/2012 Biomarkers to combat lung cancer A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
Press release - 06/05/2010 Second Biomarker Expert Meeting in Heidelberg Numerous experts in molecular diagnostics convened at the Second Workshop of the Biomarker Discovery Center (BDC) in Heidelberg. More than 40 researchers from universities, hospitals and industry from various regions of Germany made their way to the city despite adverse travel conditions caused by the volcanic ash cloud.https://www.gesundheitsindustrie-bw.de/en/article/press-release/second-biomarker-expert-meeting-in-heidelberg
Press release - 02/06/2010 Meet and Match Event: Biomarker Last 26th of May in Mulhouse (France), 35 players of the industrial and academic domain experienced our first Meet&Match with the thematic: biomarkers. 14 speakers coming from all over the trinational BioValley presented their work during 12 minutes in front of a highly qualified and interested audience. https://www.gesundheitsindustrie-bw.de/en/article/press-release/meet-and-match-event-biomarker
Article - 20/04/2009 Biomarkers for the identification of metastases Prof. Dr. Heike Allgayer a surgeon and molecular biologist from Heidelberg is investigating the molecular processes of the formation of tumour metastases. A major objective of her research is to find specific biomarkers that enable the early identification of metastases and to monitor the outcome of therapy. She has already received numerous prizes for her achievements.https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-for-the-identification-of-metastases
Article - 30/09/2013 Healthy hearts in old age Coordinated by the Department of Cardiology at the University of Heidelberg, the EU-funded interdisciplinary project “BestAgeing” is focussed on the identification of biomarkers for diagnosing heart disease in elderly patients. The research partners hope that the combination of several biomarkers will allow a more accurate diagnosis of heart disease, resulting in a more efficient and effective treatment of elderly patients.https://www.gesundheitsindustrie-bw.de/en/article/news/healthy-hearts-in-old-age
Press release - 04/09/2008 Rhine Neckar Biotechnology Cluster wins German Top Cluster Contest The Rhine-Neckar biotechnology cluster BioRN was distinguished as one of the five most significant high-tech regions in Germany and will receive part of the 200 million Euro federal grant. https://www.gesundheitsindustrie-bw.de/en/article/press-release/rhine-neckar-biotechnology-cluster-wins-german-top-cluster-contest
Article - 25/02/2010 Molecular marker for the treatment of lung cancer Whether the treatment of lung cancer with therapeutic antibodies is successful or not largely depends on the genetic makeup of the tumour. There is a need for reliable biomarkers that can predict patients’ response to treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-marker-for-the-treatment-of-lung-cancer
Article - 13/11/2010 Evidence in personalised medicine Personalised medicine is the potential capacity to systematically use information about an individual patient in order to select or optimise that patient’s therapeutic care and tailor individual preventive treatments. Biomarkers need to be used as objective parameters in order to determine a patient’s individual risk profile. The role that features detected by genetic tests play in the causal mechanism of diseases and whether they are suitable…https://www.gesundheitsindustrie-bw.de/en/article/news/evidence-in-personalised-medicine
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Press release - 10/08/2009 Biomarkers help predict the risk of Alzheimer’s in patients with mild cognitive impairment A large multicentre study has shown that CSF (cerebrospinal fluid) biomarkers can be used to predict, with good accuracy, as to which patients with mild cognitive impairments will develop Alzheimer’s disease. The biomarkers used are microtubule-associated proteins that are abundant in CNS neurons as well as beta amyloid, which is a peptide that forms brain plaques in people with Alzheimer’s disease. Changes in the concentrations of these proteins…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-help-predict-the-risk-of-alzheimer-s-in-patients-with-mild-cognitive-impairment
Press release - 14/09/2009 Launch of SAFE-T Consortium: Translational Safety Biomarkers "Faster Development of Safer Medicines through Translational Safety Biomarkers": On September 14, 2009, the Safer And Faster Evidence-based Translation (SAFE-T) consortium project under the EU Innovative Medicines Initiative - Joint Undertaking (IMI-JU) was presented at the EUROTOX 2009 conference in Dresden. The consortium announces the start of work to qualify biomarkers for drug-induced kidney, liver and vascular injury in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/launch-of-safe-t-consortium-translational-safety-biomarkers
Expert interview - 08/08/2018 Ludolph: diagnosing and treating neurodegenerative disorders Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine